Leerink Partnrs Issues Negative Estimate for Genfit Earnings

Genfit S.A. (NASDAQ:GNFT) – Equities research analysts at Leerink Partnrs dropped their FY2025 earnings estimates for Genfit in a report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($0.88) per share for the year, down from their prior estimate of ($0.86). The consensus estimate for Genfit’s current full-year earnings is $0.96 per share. Leerink Partnrs also issued estimates for Genfit’s FY2026 earnings at ($0.84) EPS, FY2027 earnings at ($0.35) EPS and FY2028 earnings at ($0.88) EPS.

Separately, HC Wainwright reiterated a “buy” rating and set a $13.00 target price on shares of Genfit in a research report on Friday.

Genfit Stock Performance

Shares of GNFT stock opened at $3.91 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.74 and a quick ratio of 3.74. Genfit has a 1 year low of $3.35 and a 1 year high of $6.42. The firm has a fifty day moving average price of $3.76 and a 200-day moving average price of $4.43.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.